Sugi Predict

Sugi Predict / Targets / BECN1

BECN1

Beclin-1 · Q14457 · BECN1 on Sugi Atlas →

4,560 patent compounds predicted against BECN1, 3,095 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL543112 SCHEMBL543112 0.43 8/20
SCHEMBL206442 SCHEMBL206442 0.55 7/20
SCHEMBL1059374 SCHEMBL1059374 0.45 6/20
SCHEMBL1345 SCHEMBL1345 0.41 5/20
SCHEMBL1259192 SCHEMBL1259192 0.43 4/20
SCHEMBL467281 SCHEMBL467281 0.52 3/20
SCHEMBL2274 SCHEMBL2274 0.45 3/20
SCHEMBL1024602 SCHEMBL1024602 0.45 3/20
SCHEMBL119883 SCHEMBL119883 0.33 3/20
SCHEMBL1237420 SCHEMBL1237420 0.36 2/20
SCHEMBL49226 SCHEMBL49226 0.35 2/20
SCHEMBL135811 SCHEMBL135811 0.33 2/20
Abt 737 Abt 737 (SCHEMBL158942) 1.00 1/20
Abt 737 Abt 737 (SCHEMBL170470) 1.00 1/20
SCHEMBL1540670 SCHEMBL1540670 0.93 1/20
SCHEMBL1540214 SCHEMBL1540214 0.92 1/20
SCHEMBL1540387 SCHEMBL1540387 0.92 1/20
SCHEMBL1540510 SCHEMBL1540510 0.92 1/20
SCHEMBL1540736 SCHEMBL1540736 0.92 1/20
SCHEMBL680873 SCHEMBL680873 0.91 1/20

Clinical trials — most relevant to BECN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients PHASE3COMPLETED
Clostridium Butyricum in Stenosing Crohn's Desease PHASE1/PHASE2NOT_YET_RECRUITING
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer PHASE1/PHASE2COMPLETED
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1/PHASE2COMPLETED
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients PHASE2COMPLETED
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) PHASE1/PHASE2UNKNOWN
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients PHASE2UNKNOWN
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE1COMPLETED
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma PHASE1WITHDRAWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction EARLY_PHASE1RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Evaluation of Serum Autophagic Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Individuals nanENROLLING_BY_INVITATION
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
2-A-Day Study: Twice a Day Meals Study. nanCOMPLETED
Fasting, Exercise, and Diet to Activate Autophagy in Depression nanNOT_YET_RECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Autophagy Markers in Endometrial Polyps nanCOMPLETED
The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy nanCOMPLETED
Autophagy/Apoptosis Balance in Placental Vascular Pathologies nanRECRUITING
Time Course for Fasting-induced Autophagy in Humans nanWITHDRAWN
mTORC1 and Autophagy in Human Brown Adipocytes nanCOMPLETED
Autophagy, Oxidative Stress and Hippo Signaling in Human Aortic Aneurysm nanCOMPLETED
Muscle Insulin Resistance in Aging (Mirage) nanACTIVE_NOT_RECRUITING
Strong Evidence: Digitally Delivered Exercise in Older Adults nanACTIVE_NOT_RECRUITING
Effects of Trehalose and Polyphenols in Vasculopathic Patients nanCOMPLETED
Intermittent Fasting for Pancreatitis nanNOT_YET_RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BECN1 binder may also engage these)

ProteinNameSimilarity
Q91XJ1 — 1.000 Q91XJ1 →
Q4A1L5 — 1.000 Q4A1L5 →
Q5R878 — 1.000 Q5R878 →
Q4A1L4 — 1.000 Q4A1L4 →
Q5ZKS6 — 1.000 Q5ZKS6 →
O88597 — 1.000 O88597 →
Q6GP52 — 1.000 Q6GP52 →
Q4A1L3 — 1.000 Q4A1L3 →
F1RCP1 — 0.990 F1RCP1 →
Q8IWV8 — 0.967 Q8IWV8 →
O43513 — 0.965 O43513 →
P61635 — 0.965 P61635 →
P83094 — 0.965 P83094 →
A4GWN3 — 0.964 A4GWN3 →
Q8C735 — 0.964 Q8C735 →
Q8QFR2 — 0.964 Q8QFR2 →
Q91W96 — 0.963 Q91W96 →
Q9R1D7 — 0.963 Q9R1D7 →
Q9CZB6 — 0.963 Q9CZB6 →
P42227 — 0.963 P42227 →
Q9UJ41 — 0.962 Q9UJ41 →
Q5TKA1 — 0.962 Q5TKA1 →
P58854 — 0.962 P58854 →
PARN Poly(A)-specific ribonuclease PARN 0.962 landscape →
Q9UPW8 — 0.962 Q9UPW8 →
Q2F7Z4 — 0.962 Q2F7Z4 →
Q99J31 — 0.962 Q99J31 →
Q2HJ41 — 0.962 Q2HJ41 →
O18973 — 0.961 O18973 →
Q5RAQ5 — 0.961 Q5RAQ5 →